JP2021515588A - ペプチド交換蛋白質 - Google Patents

ペプチド交換蛋白質 Download PDF

Info

Publication number
JP2021515588A
JP2021515588A JP2020560595A JP2020560595A JP2021515588A JP 2021515588 A JP2021515588 A JP 2021515588A JP 2020560595 A JP2020560595 A JP 2020560595A JP 2020560595 A JP2020560595 A JP 2020560595A JP 2021515588 A JP2021515588 A JP 2021515588A
Authority
JP
Japan
Prior art keywords
peptide
cells
cell
mhc class
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020560595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515588A5 (https=
JPWO2019145509A5 (https=
Inventor
ルイーズ ヘレン ボイル
ルイーズ ヘレン ボイル
アンドレアス ハインリッヒ ニーリンクックス
アンドレアス ハインリッヒ ニーリンクックス
フローリン チューダー イルカ
フローリン チューダー イルカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1801323.5A external-priority patent/GB201801323D0/en
Priority claimed from GBGB1813737.2A external-priority patent/GB201813737D0/en
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of JP2021515588A publication Critical patent/JP2021515588A/ja
Publication of JP2021515588A5 publication Critical patent/JP2021515588A5/ja
Publication of JPWO2019145509A5 publication Critical patent/JPWO2019145509A5/ja
Priority to JP2023213107A priority Critical patent/JP2024029012A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020560595A 2018-01-26 2019-01-25 ペプチド交換蛋白質 Pending JP2021515588A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023213107A JP2024029012A (ja) 2018-01-26 2023-12-18 ペプチド交換蛋白質

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1801323.5A GB201801323D0 (en) 2018-01-26 2018-01-26 Peptide exchange protein
GB1801323.5 2018-01-26
GBGB1813737.2A GB201813737D0 (en) 2018-08-23 2018-08-23 Peptide exchange protein
GB1813737.2 2018-08-23
PCT/EP2019/051907 WO2019145509A1 (en) 2018-01-26 2019-01-25 Peptide exchange protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023213107A Division JP2024029012A (ja) 2018-01-26 2023-12-18 ペプチド交換蛋白質

Publications (3)

Publication Number Publication Date
JP2021515588A true JP2021515588A (ja) 2021-06-24
JP2021515588A5 JP2021515588A5 (https=) 2022-01-19
JPWO2019145509A5 JPWO2019145509A5 (https=) 2022-01-19

Family

ID=65234583

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560595A Pending JP2021515588A (ja) 2018-01-26 2019-01-25 ペプチド交換蛋白質
JP2023213107A Pending JP2024029012A (ja) 2018-01-26 2023-12-18 ペプチド交換蛋白質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023213107A Pending JP2024029012A (ja) 2018-01-26 2023-12-18 ペプチド交換蛋白質

Country Status (7)

Country Link
US (1) US12397036B2 (https=)
EP (1) EP3743093A1 (https=)
JP (2) JP2021515588A (https=)
CN (1) CN111836635A (https=)
AU (1) AU2019211121B2 (https=)
CA (1) CA3089154A1 (https=)
WO (1) WO2019145509A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11814420B2 (en) 2018-07-06 2023-11-14 The Regents Of The University Of California Peptide deficient-MHC class I/chaperone compositions and methods
EP4085069A1 (en) * 2020-01-03 2022-11-09 The Regents of The University of California Systems and methods for identification of mhc-i peptide epitopes
US12534510B2 (en) 2020-04-16 2026-01-27 The Regents Of The University Of California Peptide-receptive MHC-I complex compositions and methods
WO2023163980A1 (en) * 2022-02-22 2023-08-31 The Children's Hospital Of Philadelphia Systems and methods for chaperone-mediated ligand exchange on mhc-i and mhc-related molecules using chicken tapbpr
WO2026024596A1 (en) * 2024-07-22 2026-01-29 The Children's Hospital Of Philadelphia Methods of stimulating an immune response

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017509317A (ja) * 2014-01-27 2017-04-06 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. Ｍｈｃクラスｉエピトープ送達ポリペプチド

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
US6222012B1 (en) 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1995023874A1 (en) 1994-03-01 1995-09-08 Ludwig Institute For Cancer Research Determination of cancerous conditions by mage gene expression
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US7060479B2 (en) * 1999-12-08 2006-06-13 Serono Genetics Institute, S.A. Full-length human cDNAs encoding potentially secreted proteins
US6692923B2 (en) * 1999-04-14 2004-02-17 Incyte Corporation Tapasin-like protein
AU2001260847A1 (en) 2000-05-24 2001-12-03 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
US7947436B2 (en) * 2004-12-13 2011-05-24 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
JP2011518115A (ja) * 2008-01-28 2011-06-23 タップイミューン インコーポレイテッド 免疫応答を増強するためのタパシン増加
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
CN107857819A (zh) * 2017-07-03 2018-03-30 江苏西迪尔生物技术有限公司 多功能融合蛋白及其应用
CN112469479B (zh) 2018-07-10 2024-08-13 康涅狄格大学 治疗癌症和自身免疫性疾病的试剂和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017509317A (ja) * 2014-01-27 2017-04-06 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. Ｍｈｃクラスｉエピトープ送達ポリペプチド

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
""RecName: Full=Tapasin-related protein; Short=TAPASIN-R; AltName: Full=TAP-binding protein-like; Al", UNIPROT: Q8VD31 [ONLINE], vol. entry version 116, JPN7022005941, 2017, ISSN: 0005133116 *
""RecName: Full=Tapasin-related protein; Short=TAPASIN-R; AltName: Full=TAP-binding protein-like; Al", UNIPROT: Q9BX59 [ONLINE], vol. entry version 135, JPN7022005944, 2017, ISSN: 0005133115 *
CHEN X ET AL: "The modification of tapasin enhances cytotoxic T lymphocyte activity of intracellularly delivered CT", ACTA BIOCHIM BIOPHYS SIN, vol. 45, no. 3, JPN7022005943, 2013, pages 203 - 212, ISSN: 0005133118 *
HERMANN C ET AL: "The binding of TAPBPR and tapasin to MHC Class I is mutually exclusive", JOURNAL OF IMMUNOLOGY, vol. 191, no. 11, JPN7022005942, 2013, pages 5743 - 5750, ISSN: 0005133117 *

Also Published As

Publication number Publication date
WO2019145509A1 (en) 2019-08-01
US20210052695A1 (en) 2021-02-25
JP2024029012A (ja) 2024-03-05
EP3743093A1 (en) 2020-12-02
AU2019211121B2 (en) 2024-09-12
CN111836635A (zh) 2020-10-27
US12397036B2 (en) 2025-08-26
AU2019211121A1 (en) 2020-08-27
CA3089154A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
JP2024029012A (ja) ペプチド交換蛋白質
US20210283242A1 (en) Immune-mediated coronavirus treatments
US12384828B2 (en) Engineered extracellular vesicles comprising fusion proteins
US20100159594A1 (en) Single chain trimers and uses therefor
US20230074462A1 (en) Methods and compositions for stimulating immune response
KR20200039765A (ko) T 세포 변형
JP2014509841A (ja) 癌を治療するための組成物および方法
JP2000510689A (ja) Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
US20040096429A1 (en) Method for producing cytotoxic T-cells
SA519410007B1 (ar) مركبات ببتيد وطرق لمعالجة السكر
JP4587566B2 (ja) Ｈｌａクラスｉ分子と付着手段とを含む複合体を用いた、標的細胞に対するｔ細胞応答を作出又は強化する方法
Chua et al. Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2
WO2020145222A1 (ja) 新規ネオアンチゲン及びそれらを用いたがん免疫治療薬
Truscott et al. Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptides
US20030044415A1 (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
KR20220083773A (ko) 암 항원을 포함하는 개선된 lamp 구축물
Schütz et al. MHC‐Ig induces memory T cell formation in vivo and inhibits tumour growth
Padula et al. Secreted heat shock protein gp96-Ig and OX40L-Fc combination vaccine enhances SARS-CoV-2 Spike (S) protein-specific B and T cell immune responses
WO2022216949A1 (en) Fusion protein for antigen presentation
Wang et al. Gene conjugation of molecular adjuvant C3d3 to hCGβ increased the anti‐hCGβ Th2 and humoral immune response in DNA immunization
US20260115272A1 (en) Methods and compositions for stimulating immune response
Babon et al. Cross-presentation of a CMV pp65 epitope by human dendritic cells using bee venom PLA2 as a membrane-binding vector
CN118103062A (zh) 靶向sars-cov-2抗原的肽和工程化t细胞受体及其使用方法
HK40109239A (zh) 用於活化和靶向免疫效应细胞的物质和方法
Lopez Intensifi ed and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230822